Movement Alert｜Regeneron Pharmaceuticals Intraday Rise 3.06% in Regular Trading, Libtayo Dosing Update Wins Positive EU Regulatory Recommendation

Market Focus10-20 21:45

On October 20, Regeneron Pharmaceuticals rose 3.06% in Regular Trading, trading around $804.435 per share, with turnover of $39.0102 million.

The move was supported by a clear event catalyst: the European Medicines Agency's Committee for Medicinal Products for Human Use recommended approval of an updated Libtayo dosing regimen across all approved European Union indications.

The recommendation supports 700 mg intravenous dosing every six weeks after an initial 12 weeks of 350 mg every three weeks, and also backs shortening the 350 mg infusion time to 15 to 30 minutes after a well-tolerated first 30-minute infusion. The update points to improved treatment convenience for patients and providers. A final decision from the European Commission is expected in the coming months. Earlier this month, UBS also upgraded the stock to buy and raised its price target to $978, adding supportive sentiment around the name.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment